Appointment

RNS Number:6368R
Antisoma PLC
04 November 2003

        Antisoma promotes Nick Adams to Director of Business Development



4 November 2003, London, UK: Antisoma, (LSE: ASM) the biopharmaceutical company
specialising in the development of novel anti-cancer drugs, today announces the
promotion of Mr Nicholas Adams to Director of Business Development.

Nick will lead Antisoma's business development team, for which a key focus
remains the acquisition of new products to add to Antisoma's pipeline. He has
also been appointed to Antisoma's Executive Committee, the group responsible for
the day to day running of Antisoma Research Ltd, the wholly owned subsidiary of
Antisoma plc.

Nick had held the position of Business Development Manager at Antisoma since
June 1999. In this role he negotiated a number of in-licensing deals and
established significant development collaborations. He was also an important
contributor to the negotiations leading to the formation of Antisoma's
development and commercialisation alliance with Roche in November 2002.

Nick, 39, studied at the College of Law, London and holds a BSc (Hons) in
Biology from the University of Hertfordshire. Prior to joining Antisoma he held
R&D positions at Ciba-Geigy, Eisai Ltd and Cephalon Inc.

Nick replaces Bart Wuurman, who, after five years at Antisoma, will become Chief
Executive Officer of De Novo Pharmaceuticals Ltd.

Glyn Edwards, Antisoma's CEO, said, "Nick brings invaluable expertise and
experience to his new role as Director of Business Development and I welcome him
to our senior team. I would also like to take this opportunity to thank Bart for
his excellent contribution to the company, notably his leading role in creating
our alliance with Roche."

Enquiries:

Antisoma plc
Daniel Elger, Head of Corporate Communications  Tel: [phone]

Financial Dynamics
Jonathan Birt                                   Tel: [phone]


About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel
products for the treatment of cancer. The Company fills its development pipeline
by acquiring promising new product candidates from internationally recognised
academic or cancer research institutions.  Its core activity is the preclinical
and clinical development of these drug candidates. Antisoma forms partnerships
with pharmaceutical companies to bring its products to market.  In November
2002, Antisoma signed a ground-breaking collaboration agreement with Roche to
develop and commercialise products from Antisoma's pipeline. Please visit
www.antisoma.com for further information.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

BOAFSASULSDSEEF